1y return+219.2%S&P 500 +20.9%
3y return+186.1%S&P 500 +68.5%
5y return+130.8%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2020: $222 against $200 in the S&P 500.2
Octagon Capital Advisors LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| DNTHDianthus Therapeutics Inc | $179.5M | 16.5% | −5.4% |
| DFTXDefinium Therapeutics Inc | $138.8M | 12.7% | +20.9% |
| ABVXAbivax Sa | $132.3M | 12.1% | +46.7% |
| COGTCogent Biosciences Inc | $90.9M | 8.3% | |
| ALMSAlumis Inc | $79.7M | 7.3% | |
| AVBPArrivent Biopharma Inc | $68.5M | 6.3% | |
| TSHATaysha Gene Therapies Inc | $66.0M | 6.1% | +9.4% |
| BIOABioage Labs Inc | $42.8M | 3.9% | |
| MIRMMirum Pharmaceuticals Inc | $39.7M | 3.6% | |
| KYMRKymera Therapeutics Inc | $35.5M | 3.3% | −27.1% |
| AKTSAktis Oncology Inc | $31.0M | 2.8% | |
| XENEXenon Pharmaceuticals Inc | $29.6M | 2.7% | |
| PALIPalisade Bio Inc | $21.5M | 2.0% | |
| OCULOcular Therapeutix Inc | $20.4M | 1.9% | −34.5% |
| IRONDisc Medicine Inc | $19.7M | 1.8% | |
| SMMTSummit Therapeutics Inc | $18.2M | 1.7% | New |
| Pharvaris N VCUSIP N69605108 | $15.8M | 1.4% | +176.8% |
| ANLAdlai Nortye Ltd | $10.7M | 1.0% | New |
| DTILPrecision Biosciences Inc | $10.6M | 1.0% | −39.6% |
| DBVTDbv Technologies S A | $9.4M | 0.9% | |
| FTHFaeth Therapeutics Inc | $9.0M | 0.8% | New |
| GYREGyre Therapeutics Inc | $6.3M | 0.6% | New |
| TRVITrevi Therapeutics Inc | $5.9M | 0.5% | −78.8% |
| UNCYUnicycive Therapeutics Inc | $4.7M | 0.4% | |
| CNTXContext Therapeutics Inc | $1.7M | 0.2% | −41.9% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| DNTHDianthus Therapeutics Inc | September 30, 2023 | +613.1% | $179.5M |
| COGTCogent Biosciences Inc | September 30, 2024 | +258.3% | $90.9M |
| TRVITrevi Therapeutics Inc | March 31, 2025 | +196.5% | $5.9M |
| ALMSAlumis Inc | December 31, 2025 | +188.3% | $79.7M |
| KYMRKymera Therapeutics Inc | June 30, 2025 | +162.8% | $35.5M |
| DFTXDefinium Therapeutics Inc | March 31, 2026 | +148.9% | $138.8M |
| TSHATaysha Gene Therapies Inc | March 31, 2024 | +137.3% | $66.0M |
| AVBPArrivent Biopharma Inc | March 31, 2024 | +94.5% | $68.5M |
| DTILPrecision Biosciences Inc | December 31, 2025 | +88.9% | $10.6M |
| Pharvaris N VCUSIP N69605108 | September 30, 2024 | +86.7% | $15.8M |
Sold off last quarter
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $29.8M
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $29.2M
- Terns Pharmaceuticals IncCUSIP 880881107 was $27.9M
- BBOTBridgebio Oncology Therapeut was $6.4M
- LXEOLexeo Therapeutics Inc was $6.3M
- CATXPerspective Therapeutics Inc was $3.3M
- EVMNEvommune Inc was $3.3M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +28.5% | +14.8% |
| March 31, 2026 | +18.7% | −4.6% |
| December 31, 2025 | +36.9% | +2.4% |
| September 30, 2025 | +52.9% | +7.8% |
| June 30, 2025 | +9.6% | +10.5% |
| March 31, 2025 | −17.7% | −4.6% |
| December 31, 2024 | −0.0% | +2.1% |
| September 30, 2024 | +5.6% | +5.4% |
| June 30, 2024 | −13.8% | +4.0% |
| March 31, 2024 | +7.0% | +10.0% |
| December 31, 2023 | +30.4% | +11.2% |
| September 30, 2023 | −21.7% | −3.6% |
| June 30, 2023 | +21.1% | +8.3% |
| March 31, 2023 | −0.0% | +7.0% |
| December 31, 2022 | +5.1% | +7.1% |
| September 30, 2022 | +22.3% | −5.3% |
| June 30, 2022 | −21.7% | −16.5% |
| March 31, 2022 | −21.0% | −4.9% |
| December 31, 2021 | −10.3% | +10.7% |
| September 30, 2021 | −6.6% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Octagon Capital Advisors LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1839435&type=13F-HR&dateb=&owner=include&count=40CIK 1839435
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1839435/000183943526000004/Filed August 14, 2026 · accession 0001839435-26-000004